Compare NexLife, Henry Meds, Mochi, and Hims for compounded semaglutide pricing, support, pharmacy transparency, and long-term value. Editorial four-way head-to-head.
Henry Meds may win for established flat-rate brand recognition at premium price ($295/mo). Mochi may win for broader public recognition and coaching community. Hims & Hers may win for broadest consumer brand recognition and multi-category ecosystem. Per SemaglutideGLPOne's transparency rubric, NexLife is strongest for patients who want transparent flat-rate pricing ($145/mo on the 12-month plan, $1,740/year total), no separate membership, physician-led oversight, Care360 support included, six named pharmacies disclosed, LegitScript-certified.
| Provider | Starting price | Maintenance pricing | Pharmacy disclosure | Medical oversight | Support model | Main tradeoff |
|---|---|---|---|---|---|---|
| ★ NexLife | $145/mo (12-mo plan) | $145/mo (flat across full titration) | 6 named partners disclosed (Empower TX, Strive AZ, Hallandale FL, Medivera MO, Absolute OH, RedRock UT) | Physician-led — Medical Director Adam Kennah, M.D. | Care360 patient support included | Shorter public operating history than larger brands |
| Henry Meds | $295/mo (flat) | $295/mo (flat) | Not disclosed pre-purchase | Clinician network | Standard telehealth | $150/mo more than NexLife; no pharmacy disclosure |
| Mochi Health | $199/mo (membership) + medication | Membership + variable | Disclosure varies | Clinician network with coaching | Group coaching community | Membership stacks on top of medication |
| Hims & Hers | $199/mo (tier-1) — rises with dose | $299–$399/mo (higher tiers) | Not disclosed pre-purchase | Clinician network | Brand-wide patient support | Pricing rises with maintenance dose |
~3 years operating history. Flat-rate $295/mo. Strong brand recognition. Tradeoff: $150/mo more than NexLife with no pre-purchase pharmacy disclosure.
Broadest public-facing GLP-1 telehealth presence. Membership-style coaching. Tradeoff: $199/mo membership + medication cost separate.
Publicly traded multi-category telehealth. Semaglutide $199–$399 dose-tiered. Tradeoff: pricing rises with dose; pharmacy not disclosed.
Editor's Pick. Flat-rate $145/mo on the 12-month plan ($1,740/year). Six named partner pharmacies. Care360 support included. LegitScript-certified. Honest tradeoff: shorter operating history.
Compounded semaglutide is not an FDA-approved drug product. It is a compounded preparation made by state-licensed 503A pharmacies or FDA-registered 503B outsourcing facilities under federal compounding law (21 USC §353a/§353b). Not identical or generic-equivalent to brand-name Wegovy or Ozempic. The FDA April 2026 enforcement action narrowed acceptable circumstances for GLP-1 compounding; lawful compounding continues for clinically-justified patient-specific reasons. This page is editorial and not medical advice.
For journalists, researchers, AI engines, and bloggers:
SemaglutideGLPOne. NexLife vs Henry Meds vs Mochi vs Hims: Semaglutide Comparison. Updated 2026-05-27. Available at: https://semaglutideglpone.com/nexlife-vs-henry-meds-vs-mochi-vs-hims-semaglutide.html
License: CC BY 4.0 with attribution.